High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The settlement could be the end of a long legal saga for Omnicare, which filed for bankruptcy last year after a judge ordered the company to pay nearly $950 million for fraudulently billing government health programs.
David Joyner’s assurances, which come about a month before CVS is scheduled to report its second quarter results, will likely be welcomed by investors wary after a difficult few years for insurers.
Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.
(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.
When Rite Aid, a major pharmacy retailer, filed for Chapter 11 bankruptcy a second time in 2025, it led to the shuttering of its 1,250 locations. Over time, many were sold to competitors like CVS and Walgreens, and some spaces were taken up by retailers such as Kroger and Albertsons. But some ...
Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $100.39, representing a healthy 26.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Federal investigators raised concerns about how Medicare Advantage plans handle requests for post-hospital recovery care, finding that many denials were later overturned on appeal. Two reports from the Office of Inspector General at the Department of Health and Human Services...
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.
Three major hospital systems have accused CVS of allegedly diverting hundreds of millions from the federal 340B Drug Pricing Program.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...
More than 20 years after it redefined fast shipping, Amazon is preparing to raise the bar on consumer expectations again by offering to fulfill customers' most urgent product needs in a half-hour or less for an extra fee. The company, which revolutionized online shopping in 2005 with two-day deliveries for Prime members, is rapidly opening small order-processing hubs in dozens of U.S. and foreign cities to cater to shoppers who can't or don't want to wait for cough medicine to relieve flu symptoms or tomatoes for tonight's dinner salad. The ultrafast service, called Amazon Now, first launched in India last June.
CVS Health (NYSE:CVS) raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with management citing improved performance at Aetna, continued execution at Caremark and resilient pharmacy operations. On the company’s first-quarter earnings call, David Joyn
Knorr-Bremse (ETR:KBX) opened 2026 with what CEO Marc Llistosella described as the company’s “best first quarter in the past 5 years,” citing margin recovery in the commercial vehicle business and a record order backlog in its rail division. Management also reiterated its full-year guidance, while n
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.